Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression

Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers...

Full description

Saved in:
Bibliographic Details
Published inJournal of the renin-angiotensin-aldosterone system Vol. 13; no. 1; pp. 217 - 219
Main Authors Sarafidis, Pantelis A, Ruilope, Luis M
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.03.2012
Subjects
Angiotensin Receptor Antagonists - adverse effects
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Cardiovascular Diseases - chemically induced
Humans
Kidney Diseases - chemically induced
Renin-Angiotensin System - drug effects
Risk Factors
Online AccessGet full text

Cover

More Information
Summary:Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1470-3203
1752-8976
1752-8976
DOI:10.1177/1470320312439140